Staying on a maintenance dose long-term has been associated with: Lower blood pressure Improved cholesterol levels Cardiovascular protection Freedom from food noise (constant food thoughts) For some patients at their goal weight, microdosing GLP-1 medication can be a helpful strategy for maintaining results, especially if weight loss continues at standard doses, and may also offer supportive cardiometabolic or inflammatory benefits beyond weight alone
Food stops taking up so much space in their thoughts
But technically, Mounjaro is approved to help type 2 diabetes patients lower their blood glucose levels, while Zepbound is approved for weight loss in obese adults or overweight adults with at least one underlying condition
That keeps the doctor-patient trust intact and disruptions minimal
Heres the typical timeline: Weeks 14: Appetite returns, portions creep up, cravings intensify Months 36: Visible regain of 38 kg Months 612: Accelerated regain up to two-thirds of total loss Year 2 onwards: Regain plateaus for some, but others continue gaining A Cambridge University model found that by 52 weeks, people had regained 60% of their original weight loss